Thousands of patients in England With leukemia will become the first in the world on which the pioneering “Trojan horse” that sneaks into the cancer cells will be shown.
In instructions published on Friday, National Institute for Excellence in the field of care and care (NICE) gave green light to Belantamab Mafodotin, which can stop the progress of multiple myeloma for three times as long as standard treatments.
The targeted treatment, which is given as signals every three weeks with other cancer medications, is a special type of antibodies that target cancer cells.
It has been described as a Trojan horse treatment because it works by transporting it to a cancerous cell and release a high concentration of a fatal molecule to destroy the cell from the inside.
Professor Peter Johnson, NHS The National Clinical Director of England Cancer said that the drug will change the life of patients and their families.
He said: “Miloma is an aggressive type of leukemia, but we have seen a steady improvement in expectations for patients in recent years, as we have provided new targeted treatments.”
“I am pleased that patients in England are the first to benefit from this new treatment, which has the ability to maintain cancer in the Gulf for longer years, giving people a more valuable time chance with friends and family.”
About 1500 patients will benefit annually in England with multiple myeloma, which is a healing cancer of the bone marrow, from treatment, also known as the Blenrep and is made by Glaxosmithkline.
Health officials said that the drug would be provided to patients who have advanced their cancer or failed to respond to the treatment of another initial line.
It is a great thing to see that NHS becomes the first health care system in the world to present the drug.
She said: “We have worked hard throughout the past year to agree to this treatment and know that it will turn the lives of thousands of people with malalowa.”
Paul Sylvester, 60, from Sheffield, described the effect of the drug as amazing after his transport was diagnosed in 2023. After the first treatment he received in stopping his progress in cancer, he obtained a billantaab mavodotin through an early arrival program at the Royal Halamachire Hospital.
He said: “I feel that this treatment has returned partisan balloons to the house. It was amazing – within two or three weeks, after the first dose, I was in a remission.”
Experiments indicate that the treatment, in conjunction with Portzumib and Dexamethasone, delays the development of the disease at a rate of three years on average, compared to one year for patients who take a common use of drug conquest with other treatments.
“This recommendation clarifies our commitment to obtaining the best care for patients quickly, while ensuring the value of the taxpayer,” said Helen Knight, Director of Pharmaceutical Pharmacy.
“This pioneering treatment places NHS at the forefront of cancer innovation. By harnessing the advanced” Trojan horse “technique, we offer a new hope for leukemia patients throughout the country,” said Minister of Health Karen Smith.
